BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 20711790)

  • 1. MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status.
    Sherman JH; Prevedello DM; Shah L; Raghavan P; Pouratian N; Starke RM; Lopes MB; Shaffrey ME; Schiff D
    Acta Neurochir (Wien); 2010 Nov; 152(11):1827-34. PubMed ID: 20711790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
    van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
    Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
    Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.
    Jenkinson MD; du Plessis DG; Smith TS; Joyce KA; Warnke PC; Walker C
    Brain; 2006 Jul; 129(Pt 7):1884-91. PubMed ID: 16670176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
    Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
    Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
    McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
    Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.
    Kros JM; Gorlia T; Kouwenhoven MC; Zheng PP; Collins VP; Figarella-Branger D; Giangaspero F; Giannini C; Mokhtari K; Mørk SJ; Paetau A; Reifenberger G; van den Bent MJ
    J Neuropathol Exp Neurol; 2007 Jun; 66(6):545-51. PubMed ID: 17549014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
    Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
    Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
    Gelpi E; Ambros IM; Birner P; Luegmayr A; Drlicek M; Fischer I; Kleinert R; Maier H; Huemer M; Gatterbauer B; Anton J; Rössler K; Budka H; Ambros PF; Hainfellner JA
    Mod Pathol; 2003 Jul; 16(7):708-15. PubMed ID: 12861068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.
    Zlatescu MC; TehraniYazdi A; Sasaki H; Megyesi JF; Betensky RA; Louis DN; Cairncross JG
    Cancer Res; 2001 Sep; 61(18):6713-5. PubMed ID: 11559541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas.
    Kitange G; Misra A; Law M; Passe S; Kollmeyer TM; Maurer M; Ballman K; Feuerstein BG; Jenkins RB
    Genes Chromosomes Cancer; 2005 Jan; 42(1):68-77. PubMed ID: 15472895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.
    Sonabend AM; Lesniak MS
    Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S25-32. PubMed ID: 16274268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
    Jenkinson MD; Smith TS; Joyce K; Fildes D; du Plessis DG; Warnke PC; Walker C
    Neurology; 2005 Jun; 64(12):2085-9. PubMed ID: 15985578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
    Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype.
    Jenkinson MD; Smith TS; Brodbelt AR; Joyce KA; Warnke PC; Walker C
    J Magn Reson Imaging; 2007 Dec; 26(6):1405-12. PubMed ID: 17968881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms.
    Singh VY; Chacko G; Chacko AG; Rajshekhar V
    Neurol India; 2014; 62(1):32-6. PubMed ID: 24608451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.
    Franco-Hernández C; Martínez-Glez V; de Campos JM; Isla A; Vaquero J; Gutiérrez M; Casartelli C; Rey JA
    Cancer Genet Cytogenet; 2009 Apr; 190(2):93-6. PubMed ID: 19380026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
    Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
    J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.